ATAD2B

Across TCGA pan-cancer cohorts, ATAD2B mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ATAD2B’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ATAD2B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ATAD2B is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LSCC, LUAD, and HNSC are the cancer types where ATAD2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATAD2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	II,III,IV	+0.597	<.001	8	view →
LUAD	Male	III,IV	+0.328	<.001	8	view →
HNSC	All	II,III,IV	+0.260	.002	6	view →
CCRCC	All	All	+0.328	<.001	4	view →
PDAC	Male	III,IV	−0.620	.015	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ATAD2B–LSCC

Open the LSCC breakdown →